Recored Biomedical

Recored Biomedical appears to be a China-based private biopharma company operating through Recored (Shanghai) Biomedical Co., Ltd. (瑞可迪（上海）生物医药有限公司), founded in 2021 in Shanghai. Available public drug-intelligence and company-registry sources indicate that the company is active in infectious disease and immunology-related drug development, with a small-molecule pipeline that includes HRS-5685 for HIV infection and involvement in HRS-9950 for chronic hepatitis B. The highest disclosed development stage associated with the company is Phase 2 for HRS-9950, while HRS-5685 is in Phase 1. Corporate registry data also indicate that the Shanghai entity is active and has a wholly owned Wuhan subsidiary. Public information is limited, and much of the company detail is only visible through third-party Chinese registry and pipeline databases.